Lilly completes $2.8 billion purchase of AtaiBeckley and its depression drug BPL-003

Eli Lilly and Company agreed on July 16, 2026, to acquire AtaiBeckley Inc., a clinical-stage company developing rapid-acting treatments for mental health conditions, for about $2.8 billion in upfront cash ^[1]. The companies completed the acquisition on September 11, 2026, after AtaiBeckley shareholders approved it at a special meeting held before closing ^[2].

Under the agreement, Lilly will acquire all outstanding AtaiBeckley shares for $6.75 per share in cash ^[1]. That price was a premium of about 40% to AtaiBeckley's 30-day volume-weighted average trading price through July 15, 2026, and the boards of both companies approved the transaction ^[1]. Shareholders can receive up to $2.50 more per share through contingent value rights, worth about $1.0 billion in total, if specified development and regulatory milestones are met; the release states there can be no assurance any of those payments will be made ^[1]. The transaction was not subject to a financing condition ^[1].

AtaiBeckley's lead program, BPL-003 (mebufotenin benzoate), is a synthetic form of 5-MeO-DMT given as a nasal spray for treatment-resistant depression, which the release says affects millions of people in the United States ^[1]. In a Phase 2b study, BPL-003 produced rapid and durable reductions in depressive symptoms after an in-clinic visit lasting about two hours on average, with beneficial effects persisting for months, the companies said ^[1]. The FDA has granted BPL-003 Breakthrough Therapy Designation, and Phase 3 activities have been initiated ^[1].

The pipeline also includes VLS-01, a buccal film form of DMT in an ongoing Phase 2b study, and EMP-01 ((R)-MDMA HCl) in Phase 2 development for social anxiety disorder ^[1]. AtaiBeckley is also running a discovery program aimed at non-hallucinogenic 5-HT2AR agonists ^[1]. The companies describe these therapies as designed to restore synaptic connectivity, a different mechanism from conventional antidepressants that mainly target neurotransmitter levels ^[1].

"Treatment-resistant depression persists even after multiple treatment attempts, leaving millions of people still searching for relief," said Carole Ho, Lilly executive vice president and president of Lilly Neuroscience ^[2]. "AtaiBeckley's neuroplastogens have the potential to open a new paradigm of treatment, with rapid-acting therapeutics designed to move away from chronic dosing" ^[2]. AtaiBeckley chief executive Srinivas Rao said Lilly's expertise and reach are expected to accelerate the work for people whose conditions have not responded to existing treatments ^[1].

Why it matters for patients

None of the acquired programs is a GLP-1 medicine. Lilly's GLP-1 products — Ozempic, Wegovy and Rybelsus (semaglutide) and Mounjaro and Zepbound (tirzepatide) — are not part of this transaction, and the two releases do not say the deal changes anything about those medicines, their approved uses or their availability ^[1][2]. No effect on GLP-1 prescribing, supply or pricing was announced.

The practical relevance is that Lilly, the largest maker of GLP-1 obesity and diabetes drugs, is putting money into psychiatry, a field where treatment-resistant depression remains a common problem ^[1]. The company says the experimental treatments are meant to act quickly rather than through daily chronic dosing, and the Phase 2b study of BPL-003 involved an in-clinic visit lasting roughly two hours on average ^[1][2]. That suggests a supervised clinic setting rather than a take-home prescription, though how such treatment would be delivered, staffed or paid for has not been disclosed.

BPL-003 and VLS-01 are investigational and not approved in the United States ^[1]. The terms of the contingent payments require both U.S. regulatory approval and DEA rescheduling for BPL-003 and VLS-01, but the releases do not describe their current scheduling status or what rescheduling would involve ^[1]. Phase 3 readout dates, expected approval dates and insurance coverage have not been reported. Lilly's own cautionary statement says there is no guarantee the acquisition will achieve the results discussed or yield commercially successful products ^[2].

What happens next

The contingent payments set deadlines tied to the September 11, 2026 closing ^[1][2]. Holders would receive $1.00 per share if a Phase 3 trial of VLS-01 begins before the fourth anniversary of closing, roughly September 2030 ^[1]. They would receive $0.50 per share if BPL-003 receives U.S. regulatory approval and DEA rescheduling before the fifth anniversary, roughly September 2031, and $1.00 per share if VLS-01 clears the same two steps before the seventh anniversary, roughly September 2033 ^[1]. Lilly said it will determine the accounting treatment of the transaction under GAAP at closing ^[1].